Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.

about

Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q38686619

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Eribulin efficacy based on typ ...... ated metastatic breast cancer.

@en

type

Item

label

Eribulin efficacy based on typ ...... ated metastatic breast cancer.

@en

prefLabel

Eribulin efficacy based on typ ...... ated metastatic breast cancer.

@en

P1476

Eribulin efficacy based on typ ...... ated metastatic breast cancer.

@en

P2093

Angela Prestifilippo

http://www.w3.org/2001/XMLSchema#string

Daniele Grippaldi

http://www.w3.org/2001/XMLSchema#string

Dario Giuffrida

http://www.w3.org/2001/XMLSchema#string

Giusi Blanco

http://www.w3.org/2001/XMLSchema#string

Ivana Puliafito

http://www.w3.org/2001/XMLSchema#string

Lorenzo Memeo

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

Eribulin -- a review of preclinical and clinical studies.

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

P304

5-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0017

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

11s

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28481186

http://www.w3.org/2001/XMLSchema#string